Canada Pension Plan Investment Board Acquires New Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Canada Pension Plan Investment Board purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 30,700 shares of the specialty pharmaceutical company's stock, valued at approximately $1,697,000. Canada Pension Plan Investment Board owned 0.15% of ANI Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Exchange Traded Concepts LLC raised its holdings in ANI Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company's stock valued at $684,000 after acquiring an additional 310 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of ANI Pharmaceuticals by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after purchasing an additional 412 shares during the period. Natixis Advisors LLC raised its stake in shares of ANI Pharmaceuticals by 2.3% in the fourth quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock valued at $1,028,000 after purchasing an additional 417 shares in the last quarter. US Bancorp DE lifted its position in ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after purchasing an additional 531 shares during the period. Finally, KBC Group NV boosted its stake in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after buying an additional 600 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock traded up $0.48 on Tuesday, reaching $71.23. The company's stock had a trading volume of 46,520 shares, compared to its average volume of 276,107. The business's fifty day moving average price is $64.46 and its 200 day moving average price is $59.99. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -129.62 and a beta of 0.49. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $72.29.

Insider Buying and Selling

In related news, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the completion of the sale, the senior vice president now owns 68,624 shares of the company's stock, valued at $4,131,164.80. This trade represents a 1.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Meredith Cook sold 400 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock worth $197,792 in the last 90 days. Corporate insiders own 12.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ANIP. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research note on Monday, April 21st. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price target for the company. Guggenheim reiterated a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday, April 11th. StockNews.com downgraded ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $80.13.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.